A new whitening drug has been discovered in Japan and is being tested by a company to be used in the country.

The new drug, which was discovered in a lab in Sapporo, is the first in the world to be produced in the US and the first to be marketed in Japan, according to the National Institutes of Health.

The drug, known as zinc oxide, is a whitening agent with anti-oxidant properties, which is an important component of the anti-aging and cancer-fighting effects of sun exposure.

The US National Institutes for Health, which funds the project, hopes to commercialize the drug in the next two years.

In its original form, the zinc oxides were manufactured by the pharmaceutical company Wyeth.

In the first phase of clinical trials, they were administered to a group of patients aged between 60 and 80 who had previously developed skin cancer, according the NIH.

The researchers then tested the drug against melanoma cells, and found it had a remarkable effect on the cancer cells.

It had a significant effect on melanoma growth, which had a dramatic effect on cancer cell viability, and also significantly reduced the number of melanoma tumors.

The study was published in the journal Proceedings of the National Academy of Sciences.

A second phase of trials, in which the zindones were administered directly to patients with melanoma, also showed that zindone treatment significantly reduced melanoma tumor growth.

Researchers hope to begin commercializing the drug by the end of this year, according Tochigi University.

It has not been determined whether the drug will be marketed as a dietary supplement.

The FDA has not approved zindonol.

In the meantime, the drug is being manufactured by pharmaceutical giant Pfizer, which has a license to make it in the United States.